Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2006-06-13
2006-06-13
Jones, Dameron L. (Department: 1619)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C424S001110, C424S001650, C424S001690
Reexamination Certificate
active
07060247
ABSTRACT:
A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a-moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.
REFERENCES:
patent: 4885363 (1989-12-01), Tweedle et al.
patent: 4988496 (1991-01-01), Srinivasan et al.
patent: 5428019 (1995-06-01), Edwards et al.
patent: 5686410 (1997-11-01), Albert et al.
patent: 6200546 (2001-03-01), Hoffman et al.
patent: WO 91/01144 (1991-02-01), None
patent: WO 96/03427 (1996-02-01), None
Bjisterbosch, M.K., et al., Selective Drug Delivery by Means of Receptor-Mediated Endocytosis, (1995) Quarterly J. Nucl. Med. 39:4-19.
Bushbaum, (1995) Pharmakokinetics of Antibodies and Their Radiolabels. In: Cancer Therapy with Radiolabeled Antibodies, (ed) D.M. Goldenberg, CRC Press, Boca Raton, Chapter 10, 115-140 FL.
Cai et al, Pseudononapeptide Bombesin Antagonists Containing C-Terminal Trp or Tpi, (1992) Peptides, 13:267-271.
Cai et al., Potent bombesin antagonists with C-terminal Leu-Ψ(CH-2-N)-Tac-NH2or its derivatives, (1994) Proc. Natl. Acad. Sci., 91:12664-12668.
Coy et al., Probing Peptide Backbone Function in Bombesin, (1988) J. Biolog. Chem., 263(11), 5056-5060.
Davis et al. Metabolic Stability and Tumor Inhibition of Bombesin/GRP Receptor Antagonists, (1992) Peptides, 13:401-407.
De Jong et al., Yttrium-90 and indium-111 labelling receptor binding and biodistribution of [DOTA0,D-Phe1, Tyr3] octreotide, a promising somatostatin analogue for radionuclide therapy, (1997) Eur. J. Nucl. Med., 24:368-371.
Duncan et al., Indium-111 Diethylenetriaminepentaacetic Acid-Octreotide Is Delivered in Vivo To Pancraetic, Tumor Cell, Renal, and Hepatocyte Lysosomes, (1997) Cancer Res. 57:659-671.
Eckelman Radiolabeling with technetium-99m to study high-capacity and low-capacity biochemical systems, (1995) Eur. J. Nucl. Med., 22:249-263.
Eckelman et al., (1993) The design of site-directed radiopharmaceuticals for use in drug discovery. In: Nuclear Imaging in Drug Discovery, Development and Approval (eds) H.D. Burns et al., Birkhauser Publ. Inc., Boston, MA.
Fischman et al., A Ticket to Ride: Peptide Radiopharmaceuticals, (1993) J. Nucl. Med., 34:2253-2263.
Fritzberg et al., Targeted Proteins for Diagnostic Imaging: Does Chemistry make a Difference?, (Mar. 1992) J. Nucl. Med., 33:394-397.
Frizberg et al. (1995) Radiolaeling of antibodies for targeted diagnostics. In: Targeted Delivery of Imaging Agents (ed) V.P. Torchilin, CRC Press, Boca Raton, FL, pp. 83-101.
Gali, H., Hoffman, T.J., Owen, N.K., Sieckman, G.L., and Volkert, W.A., “In Vitro and In Vivo Evaluation of 111In_Labeled DOTA_8_Aoc_BBN[7_14]NH2 Conjugate for Specific Targeting of Tumors Expressing Gastrin Releasing Peptide (GRP) Receptors”, 47th Annual Meeting—Society of Nuclear Medicine, St. Louis, MO, J.Nucl. Med., 41(5), 119P, #471, 2000.
Gali, H., Hoffman, T.J., Sieckman, G.L., Katti, K.V., and Volkert, W.A., “Synthesis, Characterization and Labeling with 99m Tc/188Re of Peptide Conjugates Containing a Dithio-Biosphosphine Chelating Agent” Bioconjugate Chemistry, 2001 12:354-363.
Gali, H., Smith, C.J., Hoffman, T.J., Sieckman, G.L., Hayes, D.L., Owen, N.K., and Volkert, W.A., “Influence of the Radiometal on the In Vivo Pharmacokinetic Properties of a Radiometal-labeled DOTA-Conjugated Peptide”, 222nd American Chemical Society National Meeting, Chicago, IL, Aug., 2001 (Accepted).
Hermanson (1996) In: Bioconjugate Techniques, Functional Targets, Academic Press, pp. 3-136.
Hoffken, (ed) (1994) In: Peptides in Oncology II, Somatostatin Analogues: Mechanisms of Aciton, Springer-Verlag, Berlin-Heidelberg, 1-136.
Hoffman, T.J., Gali, H., Sieckman, G.L., Forte, L.R., Chin, D.T., Owen, N.K., Wooldridge, J.E., and Volkert, W.A., “Development and Characterization of a Receptor-Avid 111In-Labeled Peptide for Site-Specific Targeting of Colon Cancer”, 92nd Annual Meeting of the American Association for Cancer Research, New Orleans, LA. Proceedings of the American Association for Cancer Research, vol. 42, 139, #746, Mar. 2001.
Hoffman, T.J., Li, N., Sieckman, G.L., Higginbotham, C., Ochrymoycz, L.A., Volkert, W.A., Rh-105 Bombesin Analogs: Selecive In Vivo Targeting of Prostate Cancer with a Therapeutic Radionuclide, 45thAnnual Meeting-Society of Nuclear Medicine, Jun. 1998 J. Nucl. Med., 39(5), #982, 222P.
Hoffman, T.J., Li, N., Sieckman, G., and Volkert, W.A., “Uptake and Retention of a Rh-105 Labeled Bombesin Analogue in GRP Receptor Expressing Neoplasms: An In-Vitro Study”, 44th Annual Meeting—Society of Nuclear Medicine, Jun., 1997;J.Nucl. Med., 38(5), 188P, 1997 #808.
Hoffman, T.J., Li, N., Sieckman, G., Higginbotham, C.A., and Volkert, W.A., “Evaluation of Radiolabeled (I-125 vs. Rh-105) Bombesin Analogue Internalization in Normal and Tumor Cell Lines”, 10th International Symposium on Radiopharmacology, May, 1997: Quarterly J. Nucl. Med., 41(2) Suppl#1, 5, 1997.
Hoffman, T.J., Li, N., Volkert, W.A., Sieckman, G., Higginbotham, C.A., and Ochrymowycz, L.A., “Synthesis and Characterization of Rh-105 Labeled Bombesin Analogues: Enhancement of GRP Receptor Binding Affinity Utilizing Aliphatic Carbon Chain Linkers”, 12th International Symposium on Radiopharmaceutical Chemistry, Jun., 1997.
Hoffman, T.J., Li, N., Higginbotham, C.A., Sieckman, G., Volkert, W.A., “Specific Uptake and Retention of Rh-105 Labeled Bombesin Analogues in GRP-Receptor Expressing Cells”, European Society of Nuclear Medicine, Aug., 1997; Eur. J. Nucl. Med., 24(8), 901, 1997 #30.4.
Hoffman, T.J., Quinn, T.P., and Volkert, W.A., “Radiometallated Receptor-Avid Peptide Conjugates for Specific In Vivo Targeting of Cancer”, Nuc. Med. & Biol. 28:527-539, 2001.
Hoffman, T.J., Sieckman, G., Volkert, W.A., “Targeting Small Cell Lung Cancer Using Iodinated Peptide Analogs”, 11th International Symposium on Radiopharmaceutical Chemistry, Aug., 1995; J. Label. Comp'd Radiopharm., 37:321-323, 1995.
Hoffman, T.J., Sieckman, G.L., Volkert, W.A., “Iodinated Bombesin Analogs: Effect of N-Terminal Chain Iodine Attachment on BBN/GRP Receptor Binding”, 43rd Annual Meeting—Society of Nuclear Medicine, May, 1996; J.Nucl. Med., 37(5), p185P, #850, 1996.
Hoffman, T.J., Simpson, S.D., Smith, C.J., Sieckman, G.L., Higginbotham, C., Eshima, D., Volkert, W. and Thornback, J.R. “Accumulation and Retention of 99mTc-RP591 by GRP Receptor Expressing Tumors in SCID Mice”, Congress of the European Association of Nuclear Medicine, Barcelona, Spain, Eur. J. Nucl. Med., 26(9), 1157, #PS-416, Sep., 1999.
Hoffman, T.J., Simpson, S.D., Smith, C.J., Sieckman, G.L., Higginbotham, C., Volkert, W. and Thornback, J.R. “Accumulation and Retention of 99mTc-RP527 by GRP Receptor Expressing Tumors SCID Mice”, 46th Annual Meeting—Society of Nuclear Medicine, Jun. 9, 1999, Los Angeles, CA, J.Nucl. Med., 40(5), 104P, #419, 1999.
Hoffman, T.J., Smith, C.J., Gali, H., Owen, N.K., Sieckman, G.L., Hayes, D.L., Foster, F., Volkert, W.A.,111In /90Y Radiolabeled Peptides for Targeting Prostate Cancer; A Matched Pain Gastrin Releasing Peptide (GRP) Receptor Localizing Radiopharmaceutical, 48th Annual Meeting-Society of Nuclear Medicine, #1149, Toronto, Ontario, Canada, Jun. 2001. (Accepted).
Hoffman, T.J., Smith, C.J., Gali, H., Owen, N.K., Sieckman, and Volkert, W.A., “In Vitro and In Vivo Evaluation of 111In/90Y Radiolabel
Gali Hariprasad
Hoffman Timothy J.
Sieckman Gary
Smith Charles J.
Volkert Wynn A.
Jones Dameron L.
Kohn & Associates PLLC
The Curators of the University of Missouri
LandOfFree
Gastrin receptor-avid peptide conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gastrin receptor-avid peptide conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gastrin receptor-avid peptide conjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3645136